A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma
- Authors
- Kim, Min Kyoung; Kim, Kihyun; Min, Chang-Ki; Kwak, Jae-Yong; Bae, Sang-Byung; Yoon, Sung-Soo; Lee, Je-Jung; Kim, Ki Hwan; Nam, Seung-Hyun; Mun, Yeung-Chul; Kim, Hyo Jung; Bae, Sung Hwa; Shin, Ho-Jin; Lee, Jung-Hee; Park, Joon Seong; Jeong, Seong Hyun; Lee, Mark Hong; Kim, Yang-Soo; Lee, Ho Sup; Park, Keon Woo; Lee, Won-Sik; Lee, Sang Min; Lee, Jeong-Ok; Hyun, Myung Soo; Jo, Deog Yeon; Lim, Sung-Nam; Lee, Jae Hoon; Cho, Do-Yeun; Do, Young Rok; Kim, Jeong-A; Park, Seong Kyu; Kim, Jin Seok; Kim, Soo-Jeong; Kim, Hawk; Yi, Hyeon Gyu; Moon, Joon Ho; Choi, Chul Won; Kim, Sung-Hyun; Joo, Young-Don; Kim, Hoon-Gu; Kim, Byung Soo; Park, Moo-Rim; Song, Moo-Kon; Kim, Su-Youn
- Issue Date
- 6-Jun-2017
- Publisher
- IMPACT JOURNALS LLC
- Keywords
- multiple myeloma; aged; bortezomib; drug therapy; combination
- Citation
- ONCOTARGET, v.8, no.23, pp.37605 - 37618
- Journal Title
- ONCOTARGET
- Volume
- 8
- Number
- 23
- Start Page
- 37605
- End Page
- 37618
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6003
- DOI
- 10.18632/oncotarget.16790
- ISSN
- 1949-2553
- Abstract
- Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM. Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS). Thirty-nine (22%) patients were aged >= 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. >= 2; p = 0.0002), beta(2)-microglobulin level (< 5.5 vs. = 5.5 mg/L; p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. = 35.1 mg/m(2); p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP. In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/6003)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.